Lupin is currently trading at Rs. 944.00, up by 13.70 points or 1.47% from its previous closing of Rs. 930.30 on the BSE.
The scrip opened at Rs. 944.00 and has touched a high and low of Rs. 962.45 and Rs. 944.00 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 991.80 and Rs. 875.00 respectively. The current market cap of the company is Rs. 42180.70 crore.
The promoters holding in the company stood at 46.91%, while Institutions and Non-Institutions held 40.21% and 12.60% respectively.
Lupin has received approval for its Rufinamide Oral Suspension, 40 mg/ml, from the United States Food and Drug Administration, to market a generic equivalent of Banzel Oral Suspension, 40 mg/ml, of Eisai Inc.
Rufinamide Oral Suspension, 40 mg/ml is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
